New Dean of USC Medical School Fired

Rohit Varma’s termination, following the recent resignation of his predecessor over misbehavior, came as the Los Angeles Times prepared to report on a 2003 sexual harassment case.

Oct 6, 2017
Ashley P. Taylor

FLICKR, AARON LOGANOn Thursday (October 4), the University of Southern California (USC) announced that it had fired its medical school dean, Rohit Varma, the Los Angeles Times reports. Varma is the second dean USC has lost in recent history after revelations of misconduct.

In a statement quoted by the Times, USC provost Michael Quick says that the firing is related to information provided by “Los Angeles Times and the university’s own inquiry into the matter.” The Times was about to publish an investigative story about a case in 2003 in which Varma was disciplined for sexual harassment when USC made its announcement. As of Wednesday, the Times reported, “USC had told The Times it considered the matter resolved and that it remained confident in Varma.” But by Thursday, the university reversed its opinion.

“Based on previously undisclosed information brought to the university in recent days, USC leadership has lost confidence in Dr. Rohit Varma’s ability to lead our medical school. As of today, he is no longer dean of the Keck School of Medicine,” USC Provost Michael Quick said in a statement Thursday, the Times reports.

Varma will be the second dean USC has fired or seen resign within the last two years. Carmen Puliafito, who was dean before Varma, resigned from his position as dean in 2016 after a 21-year-old woman overdosed on a date-rape drug in a hotel room with him. Yet he remained a faculty member.

See “USC to Fire Former Medical School Dean”

This summer, the university fired Puliafito after the Times published an investigation delving into his misconduct, including illegal drug use and association with criminals. After that article appeared, “current and former faculty members contacted the newspaper to express concern that Varma was overseeing the medical school given the harassment finding,” the Times writes.

Promoting faculty who have acted inappropriately toward women “damages the credibility of schools who say they want to protect students and faculty from harm,” attorney Noreen Farrell, executive director of the national nonprofit Equal Rights Advocates, tells the Times. “Who your leaders are matters.”

In 2003, USC disciplined Varma after allegations that he sexually harassed a female researcher under his supervision, according to the Times investigation, which included interviews and reviews of confidential personnel records.

The researcher accused Varma of making unwanted sexual advances toward her at a 2002 ophthalmology conference they attended together and then “retaliating against her for reporting him,” the Times reports, based on its investigation. The university then paid the researcher more than $100,000 and temporarily blocked Varma’s progress up the professional ladder.

But Varma became a full professor in 2005, and was later promoted to chair of the ophthalmology department—by Puliafito, who was dean at the time. Then, in January of this year, Varma formally took over as dean.

“Candidates from top U.S. universities were in the running for the dean’s position, raising questions about why USC elected to follow Puliafito’s troubled tenure with the appointment of a faculty member previously found to have committed misconduct,” the Times writes.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!